FOLFOX as First-line Therapy for Gastric Cancer with Severe Peritoneal Metastasis

被引：34

作者：

Masuishi, Toshiki ^{[1
]}

Kadowaki, Shigenori ^{[1
]}

Kondo, Mayumi ^{[1
]}

Komori, Azusa ^{[1
]}

Sugiyama, Keiji ^{[1
]}

Mitani, Seiichiro ^{[1
]}

Honda, Kazunori ^{[1
]}

Narita, Yukiya ^{[1
]}

Taniguchi, Hiroya ^{[1
]}

Ura, Takashi ^{[1
]}

Ando, Masashi ^{[1
]}

Mishima, Hideyuki ^{[2
]}

Muro, Kei ^{[1
]}

机构：

[1] Aichi Canc Ctr Hosp, Dept Clin Oncol, Nagoya, Aichi, Japan

[2] Aichi Med Univ, Canc Ctr, Nagakute, Aichi, Japan

来源：

ANTICANCER RESEARCH | 2017年 / 37卷 / 12期

关键词：

FOLFOX; advanced gastric cancer; peritoneal metastasis; massive ascites; inadequate oral intake; S-1 PLUS CISPLATIN; PHASE-III; OXALIPLATIN; LEUCOVORIN; 5-FLUOROURACIL; CHEMOTHERAPY; MULTICENTER; ADENOCARCINOMA; FLUOROURACIL; TRIAL;

D O I：

10.21873/anticanres.12174

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background/Aim: Severe peritoneal metastasis (PM) from advanced gastric cancer (AGC) causes massive ascites and inadequate oral intake. Because patients with severe PM are often not included in clinical trials, little is known regarding the efficacy and safety of oxaliplatin with l-leucovorin and bolus/continuous infusion of 5-fluorouracil (FOLFOX) for them. Patients and Methods: We retrospectively studied AGC patients with massive ascites and/or inadequate oral intake due to severe PM treated with FOLFOX as the first-line treatment. Results: Only 39 (10%) of 378 AGC patients had severe PM; 10 received FOLFOX. The median progression-free and overall survivals were 7.5 and 13.2 months, respectively. Ascites decreased in seven of nine patients with ascites, and oral intake improved in four of seven patients with an inadequate oral intake. Common grade 3-4 adverse events included neutropenia and anemia. Conclusion: This study suggests that FOLFOX is effective and manageable for AGC patients with severe PM.

引用

页码：7037 / 7042

页数：6

共 21 条

[1]

Bang YJ, 2010, LANCET, V376, P1302

[2] A randomized phase II study of vismodegib (V), a hedgehog (HH) pathway inhibitor, combined with FOLFOX in patients (pts) with advanced gastric and gastroesophageal junction (GEJ) carcinoma: A New York Cancer Consortium led study [J].

Cohen, Deirdre Jill ;

Christos, Paul J. ;

Sparano, Joseph A. ;

Kindler, Hedy Lee ;

Catenacci, Daniel Virgil Thomas ;

Bekaii-Saab, Tanios B. ;

Tahiri, Sanaa ;

Janjigian, Yelena Yuriy ;

Gibson, Michael K. ;

Chan, Emily ;

Rajdev, Lakshmi ;

Urba, Susan ;

Wade, James Lloyd ;

Kozuch, Peter ;

Love, Erica ;

Vandris, Katherine ;

Takebe, Naoko ;

Hochster, Howard S. .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)

[3] Capecitabine and oxaliplatin for advanced esophagogastric cancer [J].

Cunningham, David ;

Starling, Naureen ;

Rao, Sheela ;

Iveson, Timothy ;

Nicolson, Marianne ;

Coxon, Fareeda ;

Middleton, Gary ;

Daniel, Francis ;

Oates, Jacqueline ;

Norman, Andrew Richard .

NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (01) :36-46

[4] Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 [J].

Ferlay, Jacques ;

Soerjomataram, Isabelle ;

Dikshit, Rajesh ;

Eser, Sultan ;

Mathers, Colin ;

Rebelo, Marise ;

Parkin, Donald Maxwell ;

Forman, David ;

Bray, Freddie .

INTERNATIONAL JOURNAL OF CANCER, 2015, 136 (05) :E359-E386

[5] Efficacy of sequential methotrexate and 5-fluorouracil (MTX/5FU) in improving oral intake in patients with advanced gastric cancer with severe peritoneal dissemination [J].

Imazawa, Masako ;

Kojima, Takashi ;

Boku, Narikazu ;

Onozawa, Yusuke ;

Hironaka, Shuichi ;

Fukutomi, Akira ;

Yasui, Hirofumi ;

Yamazaki, Kentaro ;

Taku, Keisei .

GASTRIC CANCER, 2009, 12 (03) :153-157

[6] Multicenter Feasibility Study of Combination Therapy with Fluorouracil, Leucovorin and Paclitaxel (FLTAX) for Peritoneal Disseminated Gastric Cancer with Massive Ascites or Inadequate Oral Intake [J].

Iwasa, Satoru ;

Goto, Masahiro ;

Yasui, Hirofumi ;

Nishina, Tomohiro ;

Takahari, Daisuke ;

Nakayama, Norisuke ;

Taira, Koichi ;

Kusaba, Hitoshi ;

Fuse, Nozomu ;

Hironaka, Shuichi ;

Shimada, Yasuhiro ;

Nakajima, Takako Eguchi .

JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2012, 42 (09) :787-793

[7] First-line fluorouracil-based chemotherapy for patients with severe peritoneal disseminated gastric cancer [J].

Iwasa, Satoru ;

Nakajima, Takako Eguchi ;

Nakamura, Kenichi ;

Takashima, Atsuo ;

Kato, Ken ;

Hamaguchi, Tetsuya ;

Yamada, Yasuhide ;

Shimada, Yasuhiro .

GASTRIC CANCER, 2012, 15 (01) :21-26

[8] Systemic chemotherapy for peritoneal disseminated gastric cancer with inadequate oral intake: a retrospective study [J].

Iwasa, Satoru ;

Nakajima, Takako Eguchi ;

Nakamura, Kenichi ;

Takashima, Atsuo ;

Kato, Ken ;

Hamaguchi, Tetsuya ;

Yamada, Yasuhide ;

Shimada, Yasuhiro .

INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2011, 16 (01) :57-62

[9] Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial [J].

Kang, Y. -K. ;

Kang, W. -K. ;

Shin, D. -B. ;

Chen, J. ;

Xiong, J. ;

Wang, J. ;

Lichinitser, M. ;

Guan, Z. ;

Khasanov, R. ;

Zheng, L. ;

Philco-Salas, M. ;

Suarez, T. ;

Santamaria, J. ;

Forster, G. ;

McCloud, P. I. .

ANNALS OF ONCOLOGY, 2009, 20 (04) :666-673

[10] Oxaliplatin, 5-fluorouracil and leucovorin (modified FOLFOX-6) as first-line chemotherapy for advanced gastric cancer patients with poor performance status [J].

Kim, Hyeong Su ;

Kim, Jung Han ;

Kim, Hee Jun ;

Jang, Hyun Joo ;

Kim, Jin Bae ;

Kim, Ji Won ;

Jung, So Young ;

Kim, Byung Chun ;

Yang, Dae Hyun ;

Park, Soah ;

Kim, Keong Ju ;

Lee, Soon Il ;

Zang, Dae Young .

ONCOLOGY LETTERS, 2012, 3 (02) :425-428

← 1 2 3 →